What are the opening hours?

Saturday 9am - 5pm Sunday 9am - 5pm

Global CHIVA Management

Home
United States
New York, NY
Global CHIVA Management

Global CHIVA Management (GCM) is a New York-based MSO advancing CHIVA vein centers through training, operations, and global collaboration.

08/13/2026

One treatment, two timescales.
A 2024 study from Pirogov Russian National Research Medical University screened 285 patients with lower extremity arterial disease and performed detailed venous ultrasound on 222 limbs, asking a simple question: is the ipsilateral great saphenous vein still usable as a bypass conduit?
Among the 51 limbs that also had varicose veins, 42 (82.6%) were not. Of those, 24 were unsuitable due to varicose change, 6 from post-thrombotic change — and 11 (21.6% of all limbs with varicose veins) had been permanently lost to a previous ablation.
The authors note that patients treated for varicose veins are typically around twenty years younger than those who need arterial bypass. Many who underwent ablation in the past decade have not yet reached the age where that decision matters. On this basis, they propose that hemodynamic vein-sparing methods — CHIVA and ASVAL — deserve more serious evaluation, since preserving the trunk may retain graft material for future coronary or limb revascularisation.
The study does not argue that every refluxing saphenous vein should be preserved, nor against ablation. It raises a narrower question: before ablating, should the probability that this patient will one day need an autologous conduit enter the decision?
https://globalchiva.com/discovered-only-when-a-bypass-is-needed-in-one-of-every-five-limbs-with-varicose-veins-the-great-saphenous-vein-has-already-been-ablated/

08/01/2026

What if the saphenous trunk didn't have to be ablated the moment reflux is found?
The SAPTAP trial — 464 patients across seven Dutch centers, published in the British Journal of Surgery — randomized patients with symptomatic trunk incompetence and varicose tributaries to two sequences of care. One group had the tributaries excised first, with trunk ablation considered later only if symptoms persisted. The other had trunk ablation and tributary excision in a single session.
At one year, quality of life in the tributaries-first group was non-inferior, at lower cost. And only 25.6% of that group went on to need the trunk ablated — meaning nearly three-quarters never did.
Trunk ablation clearly retains its value; about a quarter of patients needed it. But the trial's real contribution is not one procedure replacing another. It converts a treatment once completed in a single session into a staged decision: treat, observe, escalate if needed.
To be clear, SAPTAP's isolated phlebectomy is not CHIVA — it involves no hemodynamic mapping or shunt classification. But it shares the same premise: finding reflux in the trunk does not mean the trunk must be ablated straight away. The question moves from "which method should ablate the trunk" to "does this trunk need ablating now?"
Read more:https://globalchiva.com/treat-the-tributaries-first-leave-the-trunk-alone-nearly-three-quarters-of-patients-needed-no-further-treatment-within-a-year/

07/27/2026

Before asking whether a treatment works, it's worth confirming that what was delivered in the study was that treatment.
A 2023 critical review in Veins and Lymphatics (Cappelli, Molino Lova, Pinelli, Franceschi) returned to the five randomized trials underpinning the most recent Cochrane systematic review on CHIVA and analyzed the treatment process in each. Their assessment: of the 419 patients allocated to the CHIVA arms, more than 200 received treatment that did not follow CHIVA principles.
This is not a claim that the statistics were wrong. It's a question about what entered the analysis. CHIVA is not a fixed set of operative maneuvers but a method of building an individualized strategy from hemodynamic assessment — identifying reflux pathways and shunt types, then deciding what to preserve, where to interrupt flow, and in what order. Where that analysis wasn't performed, the authors argue, the case may not represent CHIVA even if the record says it does.
To be clear: this is the view of the review's authors, not a conclusion of the Cochrane review itself. But it raises a question relevant well beyond CHIVA — one that any technique dependent on operator judgment and individualized planning must face when it is evaluated.
Read more:
https://globalchiva.com/in-the-five-trials-underpinning-the-cochrane-conclusion-more-than-200-patients-in-the-chiva-arms-received-treatment-that-did-not-follow-chiva-principles/

07/20/2026

The point of sparing the vein is minimal invasiveness — so the incision shouldn't grow to do it.
CHIVA requires flush ligation of the incompetent tributary. In most patients that's straightforward, but in obese patients and in thigh ligations the vein lies deeper, and exposing it can require more dissection and a larger incision than desirable.
A 2024 technical report (Faccini & Grill, Jornal Vascular Brasileiro) offers a fix: using duplex-ultrasound-guided puncture to draw the tributary closer to the skin before ligation — reducing dissection and shrinking the incision. Importantly, the authors note it changes none of CHIVA's principles, and that long-term results, while not yet known, are expected to match standard CHIVA.
It's a small, practical refinement — the kind of detail that decides whether a vein-sparing approach stays minimally invasive across harder anatomy.
Read more:https://globalchiva.com/bringing-the-vein-closer-to-the-skin-with-ultrasound-a-technical-refinement-that-makes-chiva-incisions-smaller-for-obese-patients/

07/19/2026

When an independent team compared the major varicose vein procedures, one result stood out on recurrence.
A 2024 systematic review and network meta-analysis (Juhani et al., Vascular) — 75 studies, 12,196 patients, from a Saudi team with no ties to CHIVA — compared endovenous laser, radiofrequency, mechanochemical and steam ablation, foam sclerotherapy, stripping, and CHIVA.
The standout finding: CHIVA's recurrence rate was significantly lower than radiofrequency ablation's (RR 0.35, 95% CI 0.15–0.79). RFA is itself among the most well-regarded endovenous procedures — yet on recurrence, CHIVA came out ahead.
In fairness, no single procedure led on everything: steam ablation was best for post-operative pain, mechanochemical ablation for quality of life and recovery, and the authors note a risk of bias across included studies. But on recurrence — the endpoint patients and clinicians weigh most — an independent, large-sample comparison put the vein-sparing pathway in front.
Read more: https://globalchiva.com/an-independent-network-meta-analysis-of-75-studies-chivas-recurrence-rate-is-significantly-lower-than-radiofrequency-ablations/

07/10/2026

Facebook
Compared not with yesterday's operation, but with today's mainstream one.
In a 2023 propensity-score-matched study (Lee et al., Phlebology), CHIVA was compared directly with radiofrequency ablation — the widely adopted, guideline-recommended endovenous procedure. Across clinical recurrence, ultrasound recurrence, quality of life, and complications, no significant difference was observed between the two, while the CHIVA group had a shorter hospital stay.
Two honest notes: this is single-center retrospective data (with a modest RFA arm), so "no difference detected" is not the same as "proven equivalent"; and a shorter stay reflects, at least, lower inpatient resource use at that center. Still, the comparison is closer to today's clinical choices — and CHIVA reached these outcomes while preserving the vein, rather than closing and fibrosing it.
Read more:https://globalchiva.com/a-direct-comparison-with-mainstream-radiofrequency-ablation-similar-outcomes-with-chiva-and-a-shorter-hospital-stay/

07/08/2026

Two procedures can both erase the reflux on the scan — and still leave the leg in a different state.
A 2023 hemodynamic review (Cappelli, Molino Lova, Pinelli, Franceschi) makes a careful point. Destructive procedures (stripping, ablation) and vein-sparing CHIVA can all normalize plethysmographic reflux parameters. But the available data suggest destructive procedures may reduce lower-limb compliance and impair superficial drainage — while an appropriately performed vein-sparing procedure preserves that drainage.
The authors describe a telling signal: a recurrence in which no clear reflux point can be found, appearing after the vein is destroyed, but not reported after vein-sparing treatment. Their reading: correcting reflux and maintaining drainage are two different questions — and preservation may keep a drainage capacity destruction gives up.
(This is a short mechanistic review synthesizing several studies, not a single head-to-head trial — a rationale, read as such.)
Read more: https://globalchiva.com/both-normalize-reflux-parameters-yet-destroying-the-vein-may-leave-a-problem-preservation-does-not/

07/02/2026

A pre-operative flow sign that spares nearly half of these patients a second operation.
CHIVA 2 treats a great saphenous vein type III shunt in two steps — disconnecting the incompetent tributary first, and only later disconnecting the vein from the deep system if reflux returns. The staging protects the vein's drainage, but it has meant waiting to see who needs the second step.
A 2024 study (Cappelli, Molino Lova, Pinelli, Franceschi) found a way to predict it: when anterograde flow is detectable along the whole course of the saphenous vein before surgery, the vein stays stable after the first step alone — and up to ~45% of these cases never need the second.
The deeper point: CHIVA reads flow, not just anatomy. The same hemodynamic assessment can be used prospectively, to match each patient with precisely the intervention they need — turning preservation into an increasingly precise practice.
Read more: https://globalchiva.com/a-preoperative-flow-signal-may-indicate-that-some-type-iii-shunt-patients-can-remain-stable-after-a-single-step/

06/30/2026

When a leading institution maps the whole treatment landscape — and CHIVA is on the map.
In a 2025 review of venous insufficiency treatment published in Current Cardiology Reports, a Cleveland Clinic vascular surgery team surveyed the full range of options: radiofrequency and laser ablation, non-thermal techniques, sclerotherapy, and surgery. Alongside these, the review notes that for early-stage patients for whom preserving the saphenous vein is a priority, vein-sparing techniques such as CHIVA may be considered.
It's a conditional mention, not a focused endorsement. But the significance is positional: CHIVA now appears in a landscape review from a leading, unaffiliated institution, named alongside the mainstream procedures — and placed in the very category, vein preservation, that the field is increasingly re-valuing.
Read more: https://globalchiva.com/when-cleveland-clinic-maps-the-venous-treatment-landscape-chiva-appears-among-the-preserve-the-saphenous-vein-options/

06/25/2026

Preserve the vein — and still rank out front.
When researchers placed all the major varicose vein procedures into a single network meta-analysis (39 RCTs, 6,917 limbs) — stripping, laser, radiofrequency, sclerotherapy, and CHIVA — and compared them on long-term outcomes, CHIVA ranked highest for successful treatment and had the highest probability of achieving the lowest long-term recurrence.
It's a telling contrast: most procedures aim to remove or close the diseased vein, while CHIVA does the opposite — preserving the trunk and correcting the abnormal flow. Yet on long-term outcomes, the vein-sparing pathway ranked out front. Increasingly, CHIVA stands not as a comparator to one operation, but as an independent pathway evaluated alongside the mainstream techniques.
Read more: https://globalchiva.com/in-a-network-meta-analysis-spanning-multiple-procedures-chiva-ranks-among-the-highest-for-long-term-efficacy/

Address

36 East 36th Street
New York, NY
10016

Opening Hours

Saturday	9am - 5pm
Sunday	9am - 5pm

Website

https://globalchiva.com/

Alerts

Be the first to know and let us send you an email when Global CHIVA Management posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Global CHIVA Management:

Want your business to be the top-listed Health & Beauty Business in New York?